Pfizer adds R&D depth with $164 million Coley acquisition

Share this article:
Pfizer regroups businesses under global umbrellas
Pfizer regroups businesses under global umbrellas

Pfizer today said it will acquire Wellesley, MA-based Coley Pharmaceutical for $164 million to add depth to its vaccine research and boost development of drug candidates to fight cancers, allergy and asthma disorders and autoimmune diseases.

Under terms of the deal, Pfizer will make an offer of $8 a share for all of Coley's common stock, representing a premium of more than double the firm's $3 a share Thursday closing price.

“This acquisition is an important component of Pfizer's vaccine strategy and reflects our commitment to research new and more effective vaccines to prevent infectious diseases and to treat cancers and other debilitating conditions.” said Pfizer CEO Jeffrey Kindler in a statement.

Kindler added that Coley's product candidate portfolio has the potential to “significantly enhance” approaches to alzheimers, asthma, infectious disease and oncology.

The acquisition is expected to close early in 2008.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.